

## MEMO

LabCorp Drug Development  
Central Laboratory Services

To Whom It May Concern,

New care models for patients have emerged, and healthcare services are increasingly delivered through different ways. This necessitates a shift towards a more flexible approach in the regulation of Singapore's healthcare system.

Healthcare Services Act (HCSA) better safeguards patient safety and well-being in the changing healthcare environment, while enabling the development of new and innovative healthcare services.

Under HCSA, the regulatory scope is broadened to potentially include a wider scope of healthcare services such as Clinical Laboratory Service which applies to Labcorp Central Laboratory Services (CLS) Singapore.

HCSA has replaced the Private Hospitals & Medical Clinics Act (PHMCA) during Phase 1 implementation on 03 January 2022. Both HCSA and PHMCA are administrated by Singapore Ministry of Health (MOH).

With this replacement, current licensee under PHMCA has transited to HCSA. The attached is our new HCSA license certificate for CLS Singapore. This memo is to provide clarity on the replacement of license from PHMCA to HCSA.

More information on HCSA can be found at MOH's website below.

<https://www.moh.gov.sg/hcsa/about-hcsa>

---

**Tracy Yanping Liu**

Director, ED/CTTS QA Asia-Pac  
Quality Assurance

---

**Claudine Rigal**

Senior Director, Lab Ops, APAC,  
General Laboratory